NDA 022577 · Gilead Sciences INC
Viread
Tenofovir Disoproxil Fumarate · Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 24, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jan 18, 2012
Approved uses
6
Original approval plus efficacy supplements
Registered trials
1,145
277 Phase 3, 53 recruiting
FAERS reports
32,964
30,987 serious, 1,955 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely in HBV-infected patients who...
What it is approved for
From the label in effect Feb 18, 2025.
VIREAD is a nucleotide analog HIV-1 reverse transcriptase inhibitor and an HBV reverse transcriptase inhibitor and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. ( 1.1 ) for the treatment of chronic hepatitis B in adults and pediatric patients 2 years and older weighing at least 10 kg. ( 1.2 ) 1.1 HIV-1 Infection VIREAD is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. 1.2 Chronic Hepatitis B VIREAD is indicated for the treatment of chronic hepatitis B virus (HBV) in adults and pediatric patients 2 years of age and older weighing at least 10 kg .
Mechanism: Tenofovir disoproxil fumarate is an antiviral drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 11, 2018 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- May 29, 2015 Supplement 7 · Efficacy LabelLetter
- Jul 24, 2013 Supplement 3 · Efficacy LabelLetter
- Aug 16, 2012 Supplement 2 · Efficacy · priority review LabelLetter
- Aug 7, 2012 Supplement 1 · Efficacy LetterLabel
- Jan 18, 2012 Original approval · Type 3 - New Dosage Form · priority review OrphanSummary ReviewPediatric Clinical Pharmacology ReviewPediatric Medical Review
1 products under this application
- VIREAD · TENOFOVIR DISOPROXIL FUMARATE 40MG/SCOOPFUL · POWDER, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tenofovir Disoproxil" as an intervention, any sponsor and status, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- Expanded PrEP Implementation in Communities in NSWPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT02870790 · 9,733 participants · Start Mar 2016 · Primary completion Mar 2019
Drug: TDF/FTC · For: HIV; STI
Sites: Canberra, Australia; Albury, Australia; Alexandria, Australia · 31 sites in all
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort ApproachNot yet recruiting
The Task Force for Global HealthAcademic, hospital or other
NCT07258251 · 6,000 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2028
Drug: Tenofovir Alafenamide (TAF) · For: Chronic Hepatitis B; Hepatitis B Virus Infection
Sites: Phichit, Thailand
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in WomenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00705679 · 5,029 participants · Start Aug 2009 · Primary completion Aug 2012
Drug: Emtricitabine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate placebo and 4 more · For: HIV Infections
Sites: Johannesburg, South Africa; Asherville, South Africa; Chatsworth, South Africa · 15 sites in all
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05182463 · 5,000 participants (planned) · Start Jan 8, 2022 · Primary completion Dec 13, 2026
Drug: Peginterferon Alfa-2B; Nucleoside Analogs · For: Hepatitis B, Chronic
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased10,696
- renal injury9,285
- skeletal injury8,338
- chronic kidney disease7,310
- osteonecrosis7,271
- bone loss7,084
- multiple fractures6,842
- renal failure6,700
- osteoporosis5,420
- tooth loss4,538
- pain3,040
- emotional distress2,861
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 578 |
| 2005 | 639 |
| 2006 | 526 |
| 2007 | 566 |
| 2008 | 530 |
| 2009 | 573 |
| 2010 | 473 |
| 2011 | 556 |
| 2012 | 495 |
| 2013 | 530 |
| 2014 | 932 |
| 2015 | 1,213 |
| 2016 | 1,209 |
| 2017 | 1,322 |
| 2018 | 1,506 |
| 2019 | 1,938 |
| 2020 | 12,186 |
| 2021 | 2,741 |
| 2022 | 1,734 |
| 2023 | 1,093 |
| 2024 | 751 |
| 2025 | 589 |
| 2026 | 279 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viread (Tenofovir Disoproxil Fumarate)
2024 spending
$2.9M
Beneficiaries
296
1,825 claims
Per beneficiary
$9,848
$38.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,423,975 |
| 2021 | $4,643,114 |
| 2022 | $4,181,793 |
| 2023 | $3,626,217 |
| 2024 | $2,915,026 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis.
Pan CQ, Zhu L, Yu AS, et al. · Clin Infect Dis 2024 · Comparative Study, Systematic Review
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
Marzinke MA, Han K, Hanscom B, et al. · Antimicrob Agents Chemother 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, et al. · Lancet 2020 · Clinical Trial, Phase III, Comparative Study
- Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Cooper RD, Wiebe N, Smith N, et al. · Clin Infect Dis 2010 · Meta-Analysis, Systematic Review
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.